Drugs / BALIPODECT
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT02370602 | Oct 2013 → Feb 2014 | — | Takeda | Completed | No outcome recorded |
| Phase 1 | NCT01892189 | Aug 2013 → Aug 2014 | psychotic disorder | Takeda | Completed | No outcome recorded |
| Phase 1 | NCT01879722 | Jun 2013 → Jun 2014 | schizophrenia | Takeda | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02477020 | Jul 2015 → Jul 2016 | schizophrenia | Takeda | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BALIPODECT | ChEMBL registry synonym — accepted as the source's own label CHEMBL3989972 ↗ |
| Known as | TAK-063 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01879722 ↗ |
| Action | Inhibit | “TAK-063 is a selective inhibitor of PDE10A in clinical development for the treatment of schizophrenia.” PMID 29103081 ↗ Dec 2017 |
| Modality | Small molecule | — CHEMBL3989972 ↗ |
| Route | Oral | “The purpose of this study is to characterize the safety and tolerability of TAK-063 when administered as multiple oral doses at escalating dose levels in participants with...” NCT01879722 ↗ |
| Target | PDE10A | “TAK-063 is a selective inhibitor of PDE10A in clinical development for the treatment of schizophrenia.” PMID 29103081 ↗ Dec 2017 |